University of Salamanca
If you are the contact person for this centre and you wish to make any changes, please contact us.
Full Professor of the Higher Polytechnic School of Zamora, University of Salamanca
Professor in the department of Applied Physics and member of the research group on Applications of Lasers and Photonics (ALF) at the University of Salamanca
Head of the Degenerative Disorders of the Visual System group at the Castile and León Institute of Neuroscience and professor at the University of Salamanca
Professor in the Department of Animal Biology, Parasitology, Ecology, Soil Science and Agricultural Chemistry at the University of Salamanca.
Head of the Haematology Department at the University Hospital of Salamanca and Professor of Medicine at the University of Salamanca
Head of the Allergy Service at the University Hospital of Salamanca, Professor at the Faculty of Medicine of the University of Salamanca and President of the Spanish Society of Allergology and Clinical Immunology
Emeritus Professor of Biochemistry and Molecular Biology at the University of Salamanca
Full Professor of Pharmacology and researcher in the Neuroendocrinology and Obesity group at the University of Salamanca
Researcher at the Department of Applied Physics and member of the research group on Laser Applications and Photonics (ALF) at the University of Salamanca
Professor of Applied Physics in the Optics area
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness and there is no treatment that can restore vision. Now, an international team has tested a device that combines a small wireless chip implanted in the back of the eye with high-tech glasses. The scientists have managed to partially restore vision in people with an advanced form of the disease. Specifically, 26 of the 32 people who completed the trial had clinically significant improvement and were able to read. The results are published in the journal NEJM.
An article published in Nature Medicine outlines the new framework for pharmacologically treating obesity and its complications established by the European Association for the Study of Obesity (EASO). The new guidelines establish semaglutide and tirzepatide as first-line treatment for this disease and most associated conditions. The team of authors, with Spanish participation, reviewed the scientific evidence on the effects of drugs on total weight loss and its complications and designed an algorithm to help medical personnel guide treatment, taking into account each patient's medical history and the action profiles of available medications.
A team from Sweden has analysed post mortem brain samples from people aged between 0 and 78 using various techniques and found that, although it varies between individuals, new neurons continue to form in the hippocampus with no apparent age limit. Although previous studies had reached similar conclusions, controversy remains about these results. According to the authors, the new work ‘provides an important piece of the puzzle in understanding how the human brain works and changes throughout life.’ The results are published in the journal Science.
The use of GLP-1 analog diabetes drugs-such as semaglutide, sold under the trade name Ozempic-is not linked to an increased risk of suicide, according to two studies published in JAMA Internal Medicine. The first, led by a U.S. team, analyzes data from more than 3,300 people who have participated in clinical trials. The second analyzes data from 124,517 users of these drugs in Sweden and Denmark, and compares them with an even larger group of people who used another type of diabetes medication.
A paper published today in the journal Science explores the potential of glucagon-like peptide-1 (GLP-1)-based drugs such as semaglutide to treat diseases beyond diabetes and obesity. For example, recent studies suggest that they could improve conditions ranging from depression to neurological disorders to cardiovascular and kidney disease.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation in the European Union for Eurneffy (epinephrine), the first nasally administered medicine for the emergency treatment of allergic reactions. Anaphylaxis is the most severe form of allergic reaction that can occur within minutes of exposure to an allergen and can be life-threatening. Until now, treatment with epinephrine (also known as adrenaline) to reduce the anaphylactic reaction is done by intramuscular injection.
The Spanish Agency of Medicines and Health Products (AEMPS) has announced that the anti-obesity drug Wegovy (semaglutide) will be available, with a doctor’s prescription, starting from May. It is the same active ingredient as Ozempic, but for patients without diabetes.
A multidisciplinary study involving several Spanish research groups has preclinically tested a new type of immunotherapy for multiple myeloma. Instead of modifying T cells to attack the tumour directly, as CAR-T cells do, they have managed to make them secrete bispecific antibodies, which bind to the tumour on one side and to other T cells on the other, attracting them to the tumour. According to the authors, this cell therapy was more effective than traditional CAR-Ts and could generate less resistance. The results are published in the journal Science Translational Medicine.
Two teams of researchers have separately described a population of memory lymphocytes that may be responsible for the persistence of allergies over time. The work has analysed responses to allergens such as those present in peanuts, dust and birch. According to the authors, whose research is published in Science Translational Medicine, these cells could serve as a target for the treatment of various types of allergies.
The Royal Swedish Academy of Sciences has awarded the 2023 Nobel Prize in Physics to Pierre Agostini, Ferenc Krausz and Anne L'Huillier for developing "experimental methods generating attosecond light pulses". These advances made it possible to observe the motion of particles in atoms on the shortest time scale captured by humans. An attosecond is a unit of time equivalent to one trillionth of a second, roughly the time it takes light to travel the diameter of an atom.